T16157 |
MT-802
|
2231744-29-7
|
97%
|
|
MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
|
T14550 |
BETd-260
|
2093388-62-4
|
96.76%
|
|
BETd-260, a PROTAC linked by a Cereblon ligand and a BET ligand, has an inhibitory effect on BRD4 protein in leukemic cell lines.
|
T11980 |
MD-224
|
2136247-12-4
|
100%
|
|
MD-224 is a highly potent and efficacious MDM2 degrader based on the proteolysistargeting chimera (PROTAC) concept,and as a new class of anticancer agent.
|
T5440 |
Dbet57
|
1883863-52-2
|
|
|
dBET57 is heterobifunctional degrader of BRD4 based on the PROTAC technology, exhibits significant degradation of BRD4BD1 with a DC50/5h of 500 nM ,and inactive ...
|
T13954 |
UNC6852
|
2688842-08-0
|
98%
|
|
UNC6852 contains an EED ligand (IC50 = 247 nM) and a von Hippel-Lindau ligand and is a selective polycomb repressive complex 2 (PRC2) degrader based on PROTAC.
|
T5437 |
Gefitinib-based PROTAC 3
|
2230821-27-7
|
98%
|
|
Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(...
|